Kamada Ltd. - Ordinary Shares (KMDA): Price and Financial Metrics


Kamada Ltd. - Ordinary Shares (KMDA)

Today's Latest Price: $7.98 USD

0.16 (2.05%)

Updated Jun 5 4:00pm

Add KMDA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

KMDA Stock Summary

  • With a year-over-year growth in debt of 2,956.91%, Kamada Ltd's debt growth rate surpasses 98.99% of about US stocks.
  • Over the past twelve months, KMDA has reported earnings growth of -325.17%, putting it ahead of just 5.2% of US stocks in our set.
  • As for revenue growth, note that KMDA's revenue has grown 81.94% over the past 12 months; that beats the revenue growth of 93.12% of US companies in our set.
  • Stocks that are quantitatively similar to KMDA, based on their financial statements, market capitalization, and price volatility, are UTSI, AWRE, OIIM, PGNX, and MOSY.
  • Visit KMDA's SEC page to see the company's official filings. To visit the company's web site, go to www.kamada.com.
KMDA Daily Price Range
KMDA 52-Week Price Range

KMDA Stock Price Chart More Charts


KMDA Price/Volume Stats

Current price $7.98 52-week high $9.75
Prev. close $7.82 52-week low $4.40
Day low $7.81 Volume 68,597
Day high $7.99 Avg. volume 89,654
50-day MA $7.07 Dividend yield N/A
200-day MA $6.24 Market Cap 355.27M

Kamada Ltd. - Ordinary Shares (KMDA) Company Bio


Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company was founded in 1990 and is based in Ness Ziona, Israel.

KMDA Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$7.98$2001.9825566%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Kamada Ltd. To summarize, we found that Kamada Ltd ranked in the 98th percentile in terms of potential gain offered. Our DCF analysis implies the stock could yield a return of 25692.17% if fairly valued; such returns are always unlikely, though, so further investigation is likely warranted. In terms of the factors that were most noteworthy in this DCF analysis for KMDA, they are:

  • As a business, KMDA is generating more cash flow than only 23.81% of positive cash flow stocks in the Healthcare.
  • The business' balance sheet reveals debt to be 2% of the company's capital (with equity being the remaining amount). Approximately just 7.51% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • KMDA's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 54.92% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%25063%
1%25315%
2%25566%
3%25818%
4%26070%
5%26321%

NVCR, VRTX, OMI, USNU, and CORT can be thought of as valuation peers to KMDA, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


KMDA Latest News Stream


Event/TimeNews Detail
Loading, please wait...

KMDA Latest Social Stream


Loading social stream, please wait...

View Full KMDA Social Stream

Latest KMDA News From Around the Web

Below are the latest news stories about Kamada Ltd that investors may wish to consider to help them evaluate KMDA as an investment opportunity.

Kamada (KMDA) Q1 Earnings and Revenues Top Estimates

Kamada (KMDA) delivered earnings and revenue surprises of 62.50% and 8.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research | May 18, 2020

Kamada Ltd (KMDA) Q1 2020 Earnings Call Transcript

At this time, I will turn the conference over to Bob Yedid with LifeSci Advisors. Good morning, this is Bob Yedid with LifeSci Advisors. Joining me from Kamada are Amir London, Chief Executive Officer; and Chaime Orlev, Chief Financial Officer.

Yahoo | May 18, 2020

Recap: Kamada Q1 Earnings

Shares of Kamada (NASDAQ:KMDA) were flat in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share were unchanged 0.00% year over year to $0.12, which beat the estimate of $0.06.Revenue of $33,290,000 rose by 24.23% year over year, which beat the estimate of $30,120,000.Outlook Kamada hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Conference Call Details Date: May 18, 2020View more earnings on KMDATime: 08:30 AMET Webcast URL: https://www.kamada.com/events-presentations/Recent Stock Performance Company's 52-week high was at $8.00Company's 52-week low was at $4.40Price action over last quarter: Up 14.17%Company Description Kamada Ltd is a drug-focused, plasma-derived protein therapeu...

Yahoo | May 18, 2020

Kamada Reports First Quarter 2020 Financial Results and Highlights Recent Corporate Progress

Total Revenues were $33.3 Million, an Increase of 24% Year-over-YearNet Income was $5.2 Million, an Increase of 6% Year-over-YearCompany Reports Continued Progress of its.

Yahoo | May 18, 2020

Kamada to Announce First Quarter Ended March 31, 2020 Financial Results and Host Conference Call on May 18, 2020

Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the first quarter ended March 31, 2020, prior to the open of the U.S. financial markets on Monday, May 18, 2020. Kamada management will host an investment community conference call on Monday, May 18, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel), or 201-689-8263 (International) and entering the conference identification number: 13699990.

Yahoo | May 11, 2020

Read More 'KMDA' Stories Here

KMDA Price Returns

1-mo 7.40%
3-mo 40.25%
6-mo 3.64%
1-year 42.25%
3-year 4.31%
5-year 89.10%
YTD 16.84%
2019 36.60%
2018 5.26%
2017 -12.84%
2016 31.33%
2015 9.21%

Continue Researching KMDA

Want to see what other sources are saying about Kamada Ltd's financials and stock price? Try the links below:

Kamada Ltd (KMDA) Stock Price | Nasdaq
Kamada Ltd (KMDA) Stock Quote, History and News - Yahoo Finance
Kamada Ltd (KMDA) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8812 seconds.